Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
PFIZER ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PFIZER Mar-23 |
ACTAVIS Dec-18 |
PFIZER/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,662 | 16,117 | - | |
Low | Rs | 3,407 | 10,811 | - | |
Sales per share (Unadj.) | Rs | 530.0 | 3,953.4 | - | |
Earnings per share (Unadj.) | Rs | 136.4 | -1,273.4 | - | |
Cash flow per share (Unadj.) | Rs | 159.4 | 416.6 | - | |
Dividends per share (Unadj.) | Rs | 70.00 | 0 | - | |
Avg Dividend yield | % | 1.7 | 0 | - | |
Book value per share (Unadj.) | Rs | 701.0 | 16,305.9 | - | |
Shares outstanding (eoy) | m | 45.75 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.6 | 3.4 | 223.5% | |
Avg P/E ratio | x | 29.6 | -10.6 | -279.8% | |
P/CF ratio (eoy) | x | 25.3 | 32.3 | 78.3% | |
Price / Book Value ratio | x | 5.8 | 0.8 | 697.0% | |
Dividend payout | % | 51.3 | 0 | - | |
Avg Mkt Cap | Rs m | 184,576 | 4,478,069 | 4.1% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 3,317 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,804.7 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,060.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 24,248 | 1,314,899 | 1.8% | |
Other income | Rs m | 1,011 | 25,145 | 4.0% | |
Total revenues | Rs m | 25,258 | 1,340,044 | 1.9% | |
Gross profit | Rs m | 8,420 | 34,457 | 24.4% | |
Depreciation | Rs m | 1,055 | 562,091 | 0.2% | |
Interest | Rs m | 135 | 75,877 | 0.2% | |
Profit before tax | Rs m | 8,240 | -578,366 | -1.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,507 | 0.0% | |
Tax | Rs m | 2,001 | -7,330 | -27.3% | |
Profit after tax | Rs m | 6,239 | -423,530 | -1.5% | |
Gross profit margin | % | 34.7 | 2.6 | 1,325.0% | |
Effective tax rate | % | 24.3 | 1.3 | 1,916.0% | |
Net profit margin | % | 25.7 | -32.2 | -79.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 24,933 | 539,303 | 4.6% | |
Current liabilities | Rs m | 6,574 | 477,085 | 1.4% | |
Net working cap to sales | % | 75.7 | 4.7 | 1,600.2% | |
Current ratio | x | 3.8 | 1.1 | 335.5% | |
Inventory Days | Days | 93 | 20 | 477.2% | |
Debtors Days | Days | 2 | 66 | 3.4% | |
Net fixed assets | Rs m | 13,780 | 148,839 | 9.3% | |
Share capital | Rs m | 458 | 0 | - | |
Net worth | Rs m | 32,073 | 5,423,345 | 0.6% | |
Long term debt | Rs m | 0 | 1,909,756 | 0.0% | |
Total assets | Rs m | 39,031 | 8,477,923 | 0.5% | |
Interest coverage | x | 62.1 | -6.6 | -938.2% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.2 | 400.6% | |
Return on assets | % | 16.3 | -4.1 | -398.3% | |
Return on equity | % | 19.5 | -7.8 | -249.1% | |
Return on capital | % | 26.1 | -4.8 | -539.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,557 | 469,764 | 0.8% | |
From Investments | Rs m | -361 | 258,074 | -0.1% | |
From Financial Activity | Rs m | -3,458 | -806,256 | 0.4% | |
Net Cashflow | Rs m | -262 | -78,026 | 0.3% |
Compare PFIZER With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare PFIZER With: ANG LIFESCIENCES INDIA IOL CHEMICALS & PHARM. DR. REDDYS LAB ZENITH DRUGS LTD. BANDARAM PHARMA PACKTECH
Japan's Nikkei 225 led gains in Asia as markets in the region rose across the board, following Wall Street's continued rally for a second straight day.